The evolving options in metastatic castration-sensitive prostate cancer

Purpose of review Leading trials CHAARTED, STAMPEDE, GETUG-AFU15 and LATITUDE established docetaxel and abiraterone acetate addition to androgen deprivation therapy (ADT) as a treatment guideline for patients with metastatic castration-sensitive prostate cancer. Recent findings Two recent combinations, enzalutamide with ADT and apalutamide with ADT were tested in metastatic castration-sensitive prostate cancer in three randomized controlled trials. Both combinations provided survival gain, expanding our options of treatment. Moreover, additional evidence behind radiotherapy for the primary tumor in metastatic prostate cancer is emerging. Summary In this updated article, we review the data of these trials and highlight the distinctions between these therapies, in order to better personalize the care for patients with metastatic prostate cancer.